Positrigo Analysis: $14M Raised
What is Positrigo?
Ultra-compact brain PET system for dementia and neurology diagnostics
Location
Zürich, Switzerland
Employees
11-50
Founded
2018
Product Features & Capabilities
- NeuroLF brain PET system
- FDA and CE cleared for clinical use
- Ultra-compact design
- Functional brain imaging for dementia and neurology
Use Cases
Diagnose Alzheimer’s disease in outpatient clinics; Detect early-stage dementia in patients with memory decline; Image brain function in neuro-oncology patients; Monitor movement disorders with functional imaging; Support epilepsy diagnosis through metabolic activity mapping
Other Considerations
FDA cleared for breakthrough brain PET system; CE marked in Europe; First US outpatient neurology clinic to purchase NeuroLF; First university medical center in Germany to receive NeuroLF; iF Design Award 2025 winner; Series B funding of CHF 5.5 million; Swiss Accelerator grant from Innosuisse; Partnered with Bottneuro for clinical research collaboration; Published proof-of-concept in Journal of Imaging; Completed exploratory clinical study with BPET device; Received European Innovation Council (EIC) funding for breakthrough technology
See something that needs updating? Suggest edits to this profile.